Evidence map›Paper›PMID 39753406›Full record

ReviewBritish journal of anaesthesia2025

The diverse effects of ketamine, jack-of-all-trades: a narrative review.

Nicholas D Richards, Simon J Howell, Mark C Bellamy, James Beck

Registry-linked trialAbstract readReview
In one paragraph

Review in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07145775 (Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine Combination for Epidural Labor Analgesia and Neonatal Outcomes), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07145775 phase4completednot on this map

Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine Combination for Epidural Labor Analgesia and Neonatal Outcomes: a Pilot Randomized Trial

TypeinterventionalSponsorPeking University First HospitalRan2025 to 2026Enrolled300ConditionsEpidural Analgesia, Labor Pain, Sufentanil, DexmedetomidineArmssufentanil-ropivacaine combination, dexmedetomidine-esketamine-ropivacaine combination 1, dexmedetomidine-esketamine-ropivacaine combination 2
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Intramuscular Ketamine Pharmacokinetics in Humans: A Review.European journal of drug metabolism and pharmacokinetics · 2026
    Review
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicholas D RichardsAdult Critical Care, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Medical Research, University of Leeds, Leeds, UK. Electronic address: Nicholas.richards5@nhs.net.
Simon J HowellLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Mark C BellamyAdult Critical Care, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
James BeckAdult Critical Care, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketamine, an N-methyl-D-aspartic acid receptor antagonist that was first discovered in 1962, has become established in anaesthesia providing dose-dependent anaesthetic, sedative, and analgesic effects. Ketamine, however, also acts on a wide range of other cellular targets, resulting in interesting and diverse effects on both physiological and pathological processes. Potential beneficial properties of ketamine include cardiovascular stability for patients undergoing sedation or anaesthesia, analgesia in both acute and chronic pain, bronchodilation in severe refractory asthma, anti-inflammatory properties particularly in sepsis, tumour inhibition, and antidepressant properties with marked ability to reverse suicidal ideation. The reluctance to adopt ketamine into routine practice is likely attributable in part to the stigma and negative reputation associated with its perceived side-effects and potential for abuse. This review explores the diverse properties and therapeutic potentials of ketamine being investigated across different fields whilst also identifying areas for ongoing and future research. Given the diverse range of potential benefits and promising early work, ketamine should be the focus of ongoing research in multiple different specialty areas. This includes areas relevant to anaesthesia and perioperative medicine, such as acute and chronic pain management, ICU sedation, and even tumour suppression in those undergoing surgical resection of malignancies.

Indexed as

AnalgesicsAnesthetics, DissociativeKetamineHumansAnalgesicsAnesthetics, DissociativeKetamineanaesthesiaanalgesiaantidepressant effectsanti-inflammatory propertiesketamineNMDA receptor antagonistsedationtumour suppression

Identifiers

PMID39753406
PMCPMC11867090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.